% IMPORTANT: The following is UTF-8 encoded. This means that in the presence % of non-ASCII characters, it will not work with BibTeX 0.99 or older. % Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or % “biber”. @ARTICLE{Safi:289462, author = {S. Safi and J. Krzykalla$^*$ and H. Hoffmann and A. Benner$^*$ and H. Bischoff and M. Eichhorn and M. Kriegsmann and I. Poschke and F. Stögbauer and L. Umansky$^*$ and C. Mogler and W. Weichert and H. Winter and P. Beckhove and T. Muley}, title = {{L}ow tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: {A}n identification and validation study.}, journal = {Pulmonology}, volume = {nn}, issn = {2531-0429}, address = {Amsterdam}, publisher = {Elsevier}, reportid = {DKFZ-2024-00784}, pages = {nn}, year = {2024}, abstract = {Adjuvant platinum-based chemotherapy for completely resected non-small cell lung cancer is associated with modest improvement in survival; nevertheless, no validated biomarker exists for predicting the benefit or harm of adjuvant platinum-based chemotherapy.We simultaneously measured 27 cytokines in operative tumor specimens from a discovery cohort (n = 97) by multiplex immunoassay; half of the patients received adjuvant platinum-based chemotherapy, and the other half were observed. We tested possible prognostic and predictive factors in multivariate Cox models for overall survival (OS) and relapse-free survival (RFS), and a tree-based method was applied to detect predictive factors with respect to RFS. The results were validated in an independent validation cohort (n = 93).Fifty-two of 97 (54 $\%)$ patients in the discovery cohort and 50 of 93 (54 $\%)$ in the validation cohort received adjuvant chemotherapy; forty-four (85 $\%)$ patients in the discovery cohort and 37 (74 $\%)$ in the validation cohort received four cycles as planned. In patients with low IL-1β-expressing tumors, RFS and OS were worse after adjuvant chemotherapy than after observation. The limited effect of adjuvant chemotherapy for patients with low IL-1β-expressing tumors was confirmed in the validation cohort. Additionally, RFS and OS were prolonged by adjuvant chemotherapy only in patients with high IL-1β-expressing tumors in the validation cohort.This study identified and validated low tumor IL-1β expression as a potential biomarker of a limited response to adjuvant platinum-based chemotherapy after complete resection of pulmonary adenocarcinoma. This finding has the potential to inform adjuvant treatment decisions.}, keywords = {Biomarkers (Other) / Cytokines (Other) / IL-1β (Other) / Lung neoplasms (Other) / Tumor microenvironment (Other)}, cin = {C060 / A370}, ddc = {610}, cid = {I:(DE-He78)C060-20160331 / I:(DE-He78)A370-20160331}, pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)}, pid = {G:(DE-HGF)POF4-313}, typ = {PUB:(DE-HGF)16}, pubmed = {pmid:38614857}, doi = {10.1016/j.pulmoe.2024.03.003}, url = {https://inrepo02.dkfz.de/record/289462}, }